F2RL1 and cancer: Notably, the upregulation of PAR-2 has been shown to attenuate the cytotoxic efficacy of chemotherapeutic agents by activating STAT3 and MAPK pathways, both of which promote survival and reduce apoptosis in cancer cells [20,21,22].